PTC Therapeutics (NASDAQ:PTCT)‘s stock had its “buy” rating reaffirmed by William Blair in a research report issued to clients and investors on Tuesday, November 26th, AnalystRatings.com reports.
Other equities analysts have also recently issued research reports about the company. Royal Bank of Canada reaffirmed a “buy” rating on shares of PTC Therapeutics in a report on Tuesday, September 24th. Cowen reaffirmed a “hold” rating on shares of PTC Therapeutics in a research report on Wednesday, October 30th. Credit Suisse Group reissued a “buy” rating and issued a $54.00 price target on shares of PTC Therapeutics in a research report on Thursday, October 31st. Barclays reissued a “hold” rating and issued a $43.00 target price on shares of PTC Therapeutics in a report on Monday, August 12th. Finally, TheStreet raised shares of PTC Therapeutics from a “d” rating to a “c-” rating in a research note on Tuesday, October 29th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $54.78.
PTCT traded up $0.19 during trading on Tuesday, hitting $48.57. The stock had a trading volume of 1,226,719 shares, compared to its average volume of 740,103. PTC Therapeutics has a 12 month low of $27.53 and a 12 month high of $50.96. The company has a current ratio of 4.40, a quick ratio of 4.30 and a debt-to-equity ratio of 0.44. The firm has a market cap of $2.98 billion, a PE ratio of -26.40 and a beta of 1.90. The company has a 50 day simple moving average of $45.28 and a 200-day simple moving average of $42.61.
PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.91) by ($0.15). PTC Therapeutics had a negative return on equity of 31.92% and a negative net margin of 74.86%. The company had revenue of $71.40 million during the quarter, compared to analyst estimates of $72.03 million. During the same quarter in the previous year, the business posted ($1.06) EPS. The company’s revenue was up 33.2% on a year-over-year basis. As a group, sell-side analysts anticipate that PTC Therapeutics will post -3.1 earnings per share for the current fiscal year.
In related news, CEO Stuart Walter Peltz sold 22,463 shares of the business’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $49.43, for a total value of $1,110,346.09. Company insiders own 7.00% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the business. Handelsbanken Fonder AB bought a new stake in shares of PTC Therapeutics during the 2nd quarter valued at $12,150,000. Strs Ohio increased its holdings in PTC Therapeutics by 7.3% in the second quarter. Strs Ohio now owns 14,700 shares of the biopharmaceutical company’s stock valued at $661,000 after purchasing an additional 1,000 shares during the last quarter. Quantitative Systematic Strategies LLC bought a new stake in PTC Therapeutics in the second quarter valued at about $484,000. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of PTC Therapeutics in the 2nd quarter valued at approximately $257,000. Finally, Fisher Asset Management LLC boosted its position in shares of PTC Therapeutics by 102.2% during the second quarter. Fisher Asset Management LLC now owns 267,728 shares of the biopharmaceutical company’s stock worth $12,048,000 after purchasing an additional 135,289 shares in the last quarter. Institutional investors own 99.31% of the company’s stock.
PTC Therapeutics Company Profile
PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients.
See Also: How does quantitative easing work?
Receive News & Ratings for PTC Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for PTC Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.